Armstrong AJ, Carducci MA. Chemotherapy for advanced prostate cancer: Results of new clinical trials and future studies. Curr Oncol Rep 2005;7(3):220-7. Abstract

Carducci MA, Carroll PR. Multidisciplinary management of advanced prostate cancer: Changing perspectives on referring patients and enhancing collaboration between oncologists and urologists in clinical trials. Urology 2005;65(5 Suppl):18-22. Abstract

Chaudhary UB et al. Secondary hormonal manipulations in the management of advanced prostate cancer. Can J Urol 2005;12(3):2666-76. Abstract

Efstathiou E et al. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: Efficacy, safety, and clinical benefit assessment. Urology 2005;65(1):126-30. Abstract

Figg WD et al. A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases. J Urol 2005;173(3):790-6. Abstract

Fusi A et al. Treatment options in hormonerefractory metastatic prostate carcinoma. Tumori 2004;90(6):535-46. Abstract

Goodin S et al. A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer. Cancer Chemother Pharmacol 2005;56(2):199-204. Abstract

Halabi S et al. Impact of race on survival in men with metastatic hormone-refractory prostate cancer. Urology 2004;64(2):212-7. Abstract

Higano CS. Current status of treatment for patients with metastatic prostate cancer. Can J Urol 2005;12 (Suppl 2):38-41. Abstract

Kantoff P. Recent progress in management of advanced prostate cancer. Oncology (Williston Park) 2005;19(5):631-6. Abstract

Miyake H et al. Clinical outcome of maximum androgen blockade using flutamide as secondline hormonal therapy for hormone-refractory prostate cancer. BJU Int 2005;96(6):791-5. Abstract

Miyoshi Y et al. Treatment of androgen-independent, hormone-refractory prostate cancer with docetaxel in Japanese patients. Int J Clin Oncol 2005;10(3):182-6. Abstract

Moore CN, George DJ. Update in the management of patients with hormone-refractory prostate cancer. Curr Opin Urol 2005;15(3):157- 62. Abstract

Moul JW, Chodak G. Combination hormonal therapy: A reassessment within advanced prostate cancer. Prostate Cancer Prostatic Dis 2004;7 (Suppl 1):2-7. Abstract

Paule B. Reappraisal of the concept of hormone therapy in metastatic prostate cancer and implications for treatment. Eur Urol 2005;47(6):729- 35. Abstract

Petrylak DP. The current role of chemotherapy in metastatic hormone-refractory prostate cancer. Urology 2005;65(5 Suppl):3-7. Abstract

Sato N et al; Chiba Prostate Study Group. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: Preliminary report of a prospective multicenter study. Urology 2004;64(2):341-5. Abstract

Scholz M et al. Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone. J Urol 2005;173(6):1947-52. Abstract

Tannock IF et al; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-12. Abstract

Walsh PC. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Urol 2005;173(6):1966. No abstract available